دورية أكاديمية
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
| العنوان: | Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
|---|---|
| المؤلفون: | Spanjaart, Anne Mea, Ortiz-Maldonado, Valentín, Urbano-Ispizua, Alvaro, Barba Suñol, Pere, Ljungman, Per, de la Camara, Rafael, Tridello, Gloria |
| المساهمون: | Institut Català de la Salut, Spanjaart AM Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands. Ljungman P Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden. Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. de La Camara R Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain. Tridello G Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Ortiz-Maldonado V, Urbano-Ispizua A Department of Hematology, Hospital Clínic, Barcelona, Spain. Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Springer Nature |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Avaluació de resultats (Assistència sanitària), COVID-19 (Malaltia) - Complicacions, Cèl·lules B - Tumors, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, Other subheadings::Other subheadings::Other subheadings::/complications, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento |
| الوصف: | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer hematològic; Malalties infeccioses ; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer hematológico; Enfermedades infecciosas ; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haematological cancer; Infectious diseases ; COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients. For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it is known that COVID-19 leads to severe morbidity and high mortality as compared to the general population [1–3]. For patients treated with Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell malignancies however, descriptions of the clinical course and outcome are still limited to small case series and case reports [4–8]. CAR-T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. In order to rapidly inform the medical field on the impact of COVID-19 on CAR-T-cell therapy recipients, the EBMT Infectious Diseases Working Party and the EHA Lymphoma Group joined forces and present the clinical course of COVID-19 in the largest European cohort to date. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1476-5551 |
| العلاقة: | Leukemia;35; https://doi.org/10.1038/s41375-021-01466-0Test; info:eu-repo/grantAgreement/ES/PERIS2016-2020/BDNS357800; Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hemato. Leukemia. 2021 Dec;35:3585–3588.; https://hdl.handle.net/11351/7164Test; 000715634300001 |
| DOI: | 10.1038/s41375-021-01466-0 |
| الإتاحة: | https://doi.org/10.1038/s41375-021-01466-0Test https://hdl.handle.net/11351/7164Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.A22E8A7D |
| قاعدة البيانات: | BASE |
| تدمد: | 14765551 |
|---|---|
| DOI: | 10.1038/s41375-021-01466-0 |